Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer.
Del Campo JM, Roszak A, Bidzinski M, Ciuleanu TE, Hogberg T, Wojtukiewicz MZ, Poveda A, Boman K, Westermann AM, Lebedinsky C; Yondelis Ovarian Cancer Group. Del Campo JM, et al. Ann Oncol. 2009 Nov;20(11):1794-802. doi: 10.1093/annonc/mdp198. Epub 2009 Jun 25. Ann Oncol. 2009. PMID: 19556318 Free article. Clinical Trial.
Neoadjuvant cisplatin plus temozolomide versus standard treatment in patients with unresectable glioblastoma or anaplastic astrocytoma: a differential effect of MGMT methylation.
Capdevila L, Cros S, Ramirez JL, Sanz C, Carrato C, Romeo M, Etxaniz O, Hostalot C, Massuet A, Cuadra JL, Villà S, Balañà C. Capdevila L, et al. Among authors: balana c. J Neurooncol. 2014 Mar;117(1):77-84. doi: 10.1007/s11060-013-1352-7. Epub 2014 Jan 7. J Neurooncol. 2014. PMID: 24395350 Clinical Trial.
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.
Balana C, De Las Penas R, Sepúlveda JM, Gil-Gil MJ, Luque R, Gallego O, Carrato C, Sanz C, Reynes G, Herrero A, Ramirez JL, Pérez-Segura P, Berrocal A, Vieitez JM, Garcia A, Vazquez-Estevez S, Peralta S, Fernandez I, Henriquez I, Martinez-Garcia M, De la Cruz JJ, Capellades J, Giner P, Villà S. Balana C, et al. J Neurooncol. 2016 May;127(3):569-79. doi: 10.1007/s11060-016-2065-5. Epub 2016 Feb 3. J Neurooncol. 2016. PMID: 26847813 Clinical Trial.
A Comparison of RNA-Seq Results from Paired Formalin-Fixed Paraffin-Embedded and Fresh-Frozen Glioblastoma Tissue Samples.
Esteve-Codina A, Arpi O, Martinez-García M, Pineda E, Mallo M, Gut M, Carrato C, Rovira A, Lopez R, Tortosa A, Dabad M, Del Barco S, Heath S, Bagué S, Ribalta T, Alameda F, de la Iglesia N, Balaña C; GLIOCAT Group. Esteve-Codina A, et al. Among authors: balana c. PLoS One. 2017 Jan 25;12(1):e0170632. doi: 10.1371/journal.pone.0170632. eCollection 2017. PLoS One. 2017. PMID: 28122052 Free PMC article.
SEOM clinical guidelines for anaplastic gliomas (2017).
Balañá C, Alonso M, Hernandez-Lain A, Hernandez A, Perez-Segura P, Pineda E, Ramos A, Sanchez AR, Teixidor P, Verger E, Benavides M. Balañá C, et al. Clin Transl Oncol. 2018 Jan;20(1):16-21. doi: 10.1007/s12094-017-1762-7. Epub 2017 Oct 20. Clin Transl Oncol. 2018. PMID: 29058264 Free PMC article.
Pseudoprogression as an adverse event of glioblastoma therapy.
Balaña C, Capellades J, Pineda E, Estival A, Puig J, Domenech S, Verger E, Pujol T, Martinez-García M, Oleaga L, Velarde J, Mesia C, Fuentes R, Marruecos J, Del Barco S, Villà S, Carrato C, Gallego O, Gil-Gil M, Craven-Bartle J, Alameda F; GLIOCAT Group. Balaña C, et al. Cancer Med. 2017 Dec;6(12):2858-2866. doi: 10.1002/cam4.1242. Epub 2017 Nov 3. Cancer Med. 2017. PMID: 29105360 Free PMC article.
Is a pretreatment radiological staging system feasible for suggesting the optimal extent of resection and predicting prognosis in glioblastoma? An observational study.
Capellades J, Puig J, Domenech S, Pujol T, Oleaga L, Camins A, Majós C, Diaz R, de Quintana C, Teixidor P, Conesa G, Plans G, Gonzalez J, García-Balañà N, Velarde JM, Balaña C. Capellades J, et al. Among authors: balana c. J Neurooncol. 2018 Apr;137(2):367-377. doi: 10.1007/s11060-017-2726-z. Epub 2017 Dec 28. J Neurooncol. 2018. PMID: 29285591
Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients.
Estival A, Sanz C, Ramirez JL, Velarde JM, Domenech M, Carrato C, de Las Peñas R, Gil-Gil M, Sepúlveda J, Armengol R, Cardiel I, Berrocal A, Luque R, Herrero A, Balana C. Estival A, et al. Among authors: balana c. Sci Rep. 2019 Jul 31;9(1):11125. doi: 10.1038/s41598-019-47642-2. Sci Rep. 2019. PMID: 31366977 Free PMC article. Clinical Trial.
109 results